PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 27701922-3 2016 Interestingly, we found that MPO-deficient (MPO-/-) neutrophils engulfed larger amounts of zymosan than wild-type neutrophils. Zymosan 91-98 myeloperoxidase Mus musculus 29-32 27701922-7 2016 Importantly, we found that cell surface expression of CD11b and phosphorylation of ERK1/2 was significantly higher in zymosan-stimulated MPO-/- neutrophils than in zymosan-stimulated wild-type neutrophils. Zymosan 118-125 myeloperoxidase Mus musculus 137-140 27701922-8 2016 Pretreatment with the MPO inhibitor 4-aminobenzoic acid hydrazide dramatically enhanced both zymosan phagocytosis and the surface expression of CD11b in wild-type neutrophils, but not in MPO-/- neutrophils. Zymosan 93-100 myeloperoxidase Mus musculus 22-25 25243152-5 2014 We found that agmatine treatment relieved ZYM-induced acute lung injury, as evidenced by the reduced histological scores, wet/dry weight ratio, and myeloperoxidase activity in the lung tissue. Zymosan 42-45 myeloperoxidase Mus musculus 148-163 26573963-0 2016 Myeloperoxidase negatively regulates the expression of proinflammatory cytokines and chemokines by zymosan-induced mouse neutrophils. Zymosan 99-106 myeloperoxidase Mus musculus 0-15 26573963-1 2016 OBJECTIVE: We have previously reported that myeloperoxidase-deficient (MPO(-/-)) neutrophils produce greater amounts of macrophage inflammatory protein-2 (MIP-2) upon in vitro stimulation with zymosan than wild-type neutrophils. Zymosan 193-200 myeloperoxidase Mus musculus 44-59 26573963-1 2016 OBJECTIVE: We have previously reported that myeloperoxidase-deficient (MPO(-/-)) neutrophils produce greater amounts of macrophage inflammatory protein-2 (MIP-2) upon in vitro stimulation with zymosan than wild-type neutrophils. Zymosan 193-200 myeloperoxidase Mus musculus 71-74 26573963-3 2016 METHODS: Wild-type and MPO(-/-) neutrophils isolated from peritoneal cavity were stimulated with zymosan in vitro. Zymosan 97-104 myeloperoxidase Mus musculus 23-26 26573963-7 2016 RESULTS: The MPO(-/-) neutrophils stimulated by zymosan expressed and secreted significantly higher levels of MIP-1alpha, MIP-1beta, IL-1alpha, IL-1beta, and TNF-alpha than the stimulated wild-type cells. Zymosan 48-55 myeloperoxidase Mus musculus 13-16 26573963-10 2016 In vivo, MPO(-/-) mice had significantly higher numbers of alveolar neutrophils and increased production of MIP-1alpha, MIP-1beta, IL-1alpha, IL-1beta, and TNF-alpha relative to the responses seen in wild-type mice within 24 h of zymosan administration. Zymosan 230-237 myeloperoxidase Mus musculus 9-12 22116298-0 2012 Severe neutrophil-mediated lung inflammation in myeloperoxidase-deficient mice exposed to zymosan. Zymosan 90-97 myeloperoxidase Mus musculus 48-63 23438680-0 2013 Myeloperoxidase deficiency induces MIP-2 production via ERK activation in zymosan-stimulated mouse neutrophils. Zymosan 74-81 myeloperoxidase Mus musculus 0-15 23438680-2 2013 We have previously reported that MPO-deficient (MPO(-/-)) neutrophils produce greater amount of macrophage inflammatory protein-2 (MIP-2) in vitro than do wild type when stimulated with zymosan. Zymosan 186-193 myeloperoxidase Mus musculus 33-36 23438680-6 2013 Intriguingly, we found that ERK1/2, p65, and alpha subunit of inhibitor of kappaB (IkappaBalpha) in the MPO(-/-) neutrophils were phosphorylated more strongly than in the wild type when stimulated with zymosan. Zymosan 202-209 myeloperoxidase Mus musculus 104-107 23438680-9 2013 The zymosan-induced production of MIP-2 in the wild-type neutrophils was enhanced by pre-treatment of the MPO inhibitor 4-aminobenzoic acid hydrazide. Zymosan 4-11 myeloperoxidase Mus musculus 106-109 22116298-1 2012 OBJECTIVE AND DESIGN: This study examines the role of myeloperoxidase (MPO), a major constituent of neutrophils that generates hypochlorous acid, in neutrophil recruitment into the zymosan-exposed lung of mice. Zymosan 181-188 myeloperoxidase Mus musculus 54-69 22116298-1 2012 OBJECTIVE AND DESIGN: This study examines the role of myeloperoxidase (MPO), a major constituent of neutrophils that generates hypochlorous acid, in neutrophil recruitment into the zymosan-exposed lung of mice. Zymosan 181-188 myeloperoxidase Mus musculus 71-74 22116298-6 2012 RESULTS: Zymosan exposure led to greater neutrophil infiltration into the lungs of MPO(-/-) mice relative to wild-type mice. Zymosan 9-16 myeloperoxidase Mus musculus 83-86 17172987-6 2007 TDZD-8 also attenuated the lung, liver, and pancreatic injury, the renal dysfunction caused by zymosan, and the increase in myeloperoxidase activity caused by zymosan in the lung and in the intestine. Zymosan 159-166 myeloperoxidase Mus musculus 124-139 22728595-5 2012 In the present study, we have found that MPO-KO mice exhibit more severe pulmonary inflammation than wild-type mice when challenged with an intranasal administration of zymosan. Zymosan 169-176 myeloperoxidase Mus musculus 41-44 21193041-5 2011 Olprinone also attenuated the lung, liver and pancreatic injury, renal dysfunction as well as the increased lung and intestine myeloperoxidase (MPO) activity caused by zymosan. Zymosan 168-175 myeloperoxidase Mus musculus 127-142 21193041-5 2011 Olprinone also attenuated the lung, liver and pancreatic injury, renal dysfunction as well as the increased lung and intestine myeloperoxidase (MPO) activity caused by zymosan. Zymosan 168-175 myeloperoxidase Mus musculus 144-147 20736176-3 2010 Six hours after an intraplantar injection of zymosan, Cot/tpl2(-/-) mice showed a 47% reduction in myeloperoxidase activity, concomitant with a 46% lower neutrophil recruitment and a 40% decreased luminol-mediated bioluminescence imaging in vivo. Zymosan 45-52 myeloperoxidase Mus musculus 99-114 18650782-10 2009 Fumonisin B1 also attenuated plasma markers of lung, liver and pancreatic injury, and renal dysfunction caused by zymosan and the increase in myeloperoxidase activity in the intestine caused by zymosan. Zymosan 194-201 myeloperoxidase Mus musculus 142-157 19050619-13 2009 EP also attenuated the lung, liver, and pancreatic injury and renal dysfunction caused by zymosan as well as the increase in myeloperoxidase activity in the lung and intestine caused by zymosan. Zymosan 186-193 myeloperoxidase Mus musculus 125-140 16484922-10 2006 Erythropoietin also attenuated the lung, liver, and pancreatic injury and renal dysfunction caused by zymosan as well as the increase in myeloperoxidase activity caused by zymosan in the lung and intestine. Zymosan 172-179 myeloperoxidase Mus musculus 137-152 17047518-6 2006 Myeloperoxidase activity, indicative of neutrophil infiltration, and lipid peroxidation were significantly increased in zymosan-treated wild-type mice. Zymosan 120-127 myeloperoxidase Mus musculus 0-15 15241586-8 2004 Myeloperoxidase activity indicative of neutrophil infiltration and lipid peroxidation were significantly increased in zymosan-treated WT mice. Zymosan 118-125 myeloperoxidase Mus musculus 0-15 8304241-3 1993 Edema peaked at 4-6 h, while MPO activity peaked at 24 h after zymosan application. Zymosan 63-70 myeloperoxidase Mus musculus 29-32 11748259-7 2001 MPO(-/-) mice treated with intraperitoneal zymosan had lower hepatic NO(2)Tyr/tyrosine ratios than did zymosan-treated wild-type mice. Zymosan 43-50 myeloperoxidase Mus musculus 0-3 11748259-7 2001 MPO(-/-) mice treated with intraperitoneal zymosan had lower hepatic NO(2)Tyr/tyrosine ratios than did zymosan-treated wild-type mice. Zymosan 103-110 myeloperoxidase Mus musculus 0-3 14758164-11 2004 Rosiglitazone also attenuated the lung, liver, and pancreatic injury and renal dysfunction caused by zymosan as well as the increase in myeloperoxidase activity and malondialdehyde concentrations caused by zymosan in the lung and intestine. Zymosan 206-213 myeloperoxidase Mus musculus 136-151 12879239-9 2003 PDTC also attenuated the lung, liver and pancreatic injury and renal dysfunction caused by zymosan as well as the increase in myeloperoxidase activity and malondialdehyde levels caused by zymosan in the lung, liver and intestine. Zymosan 188-195 myeloperoxidase Mus musculus 126-141 12361810-8 2002 Finally, lung tissue from MPO(-/-) mice, having tissue inflammatory responses stimulated by intraperitoneal zymosan administration, revealed less subendothelial NO(2)Tyr immunoreactivity than tissue from wild-type mice, confirming the significant role that MPO plays in catalyzing tissue nitration reactions. Zymosan 108-115 myeloperoxidase Mus musculus 26-29 11442316-4 2001 Lung, small intestine, and liver myeloperoxidase (MPO) activity, indicative of neutrophil infiltration and lipid peroxidation, were significantly increased in zymosan-treated iNOS +/+ mice. Zymosan 159-166 myeloperoxidase Mus musculus 33-48 11442316-4 2001 Lung, small intestine, and liver myeloperoxidase (MPO) activity, indicative of neutrophil infiltration and lipid peroxidation, were significantly increased in zymosan-treated iNOS +/+ mice. Zymosan 159-166 myeloperoxidase Mus musculus 50-53 10400825-4 1999 Lung, small intestine and liver myeloperoxidase (MPO) activity, indicative of neutrophil infiltration and lipid peroxidation, were significantly increased in zymosan-treated WT mice. Zymosan 158-165 myeloperoxidase Mus musculus 32-47 10400825-4 1999 Lung, small intestine and liver myeloperoxidase (MPO) activity, indicative of neutrophil infiltration and lipid peroxidation, were significantly increased in zymosan-treated WT mice. Zymosan 158-165 myeloperoxidase Mus musculus 49-52 8911920-4 1996 injection of zymosan, recruitment of polymorphonuclear leukocytes, reflected by myeloperoxidase activity in the peritoneal cavity, increased from 2 h onwards, peaked at 4 h and then decreased gradually. Zymosan 13-20 myeloperoxidase Mus musculus 80-95 8911920-5 1996 Propentofylline antagonized the zymosan-induced peritoneal myeloperoxidase accumulation in a concentration-dependent manner. Zymosan 32-39 myeloperoxidase Mus musculus 59-74 7552780-5 1995 The inflammatory response to zymosan was quantified by measuring lung myeloperoxidase activity (neutrophil recruitment). Zymosan 29-36 myeloperoxidase Mus musculus 70-85 7552780-7 1995 Unanesthetized injured mice exhibited maximal lung myeloperoxidase activity 2 h after zymosan injection (.671 +/- .07 delta OD.min-1), which was significantly attenuated (p < .01) in injured mice anesthetized with halothane (.369 +/- .054) and isoflurane (.324 +/- .055). Zymosan 86-93 myeloperoxidase Mus musculus 51-66